AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.
Also called NCT05035277
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 360 participants
- Registry
-
NCT05035277 -
2021-001554-61
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Norway
- Registry status
- Completed
Technical summary
Registry record NCT05035277. Randomized; single masking; primary purpose prevention. Start 2021-12-04 (actual); primary completion 2026-06-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
- Acronym
- ACASA-TAVI
- Condition
- Aortic Stenosis
- Intervention (Drug)
- Acetylsalicylic acid
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Edoxaban
- Lead sponsor
- Oslo University Hospital
- Collaborator
- University of Oslo
Record details
- Record id
cardio:ct-nct05035277- Content hash
fe4644b1a7b9205494c33172a213708294d4256708d9b99cf3c6c80fef063cb4